HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response View responses Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (62) Citing Articles via Google Scholar Google Scholar Articles by Yew, W. W. Articles by Lee, J. Search for Related Content PubMed PubMed Citation Articles by Yew, W. W. Articles by Lee, J.

Outcomes of Patients With Multidrug-Resistant Pulmonary Tuberculosis Treated With Ofloxacin/Levofloxacin-Containing Regimens^*

^* From the Tuberculosis and Chest Unit, Grantham Hospital (Drs. Yew, Chau, Wong, and Lee), and the Tuberculosis Service, Department of Health, Wanchai Chest Clinic (Drs. Chan, Tam, and Leung), Hong Kong, China.

Correspondence to: Wing Wai Yew, MB, FCCP, Tuberculosis and Chest Unit, Grantham Hospital, 125 Wong Chuk Hang Rd, Hong Kong, China

Objective:To analyze outcomes of patients with multidrug-resistant tuberculosis (MDR-TB) treated with ofloxacin/levofloxacin-containing regimens.

Materials and methods:From February 1990 through June 1997, 63 MDR-TB patients (with bacillary resistance to at least isoniazid and rifampin in vitro) were analyzed retrospectively. Twenty-two patients (34.9%) had had no previous antituberculosis chemotherapy. Each patient received either ofloxacin (53) or levofloxacin (10) even though 13 patients had bacilli resistant to ofloxacin in vitro. The other accompanying drugs mainly included aminoglycosides, cycloserine, ethionamide/prothionamide, and pyrazinamide. Sputum smear and culture examinations for acid-fast bacilli (AFB) were performed monthly for the initial 6 months and then at 2- to 3-month intervals until the end of treatment. Comparison was made between clinical successes and failures using univariate and multiple logistic regression analyses for the following variables: age, sex, presence of cavitation, extent of disease, sputum smear positivity, in vitro resistance to ofloxacin, in vitro resistance to streptomycin and/or ethambutol, treatment adherence, and the number of drugs per regimen.

Results:Fifty-one patients (81.0%) were cured, nine patients (14.3%) failed, and three patients (4.7%) died. For the entire group, the mean duration of treatment was 14.0 months, and the mean number of drugs was 4.7. Mean durations of chemotherapy in successful and failed patients were 14.5 and 14.2 months, respectively. Mean time for sputum smear and culture conversions were 1.7 and 2.1 months, respectively. Only cavitation, resistance to ofloxacin, and poor adherence were found to be variables independently associated with adverse outcomes (p < 0.05; odds ratios = 15.9, 13.5, 12.8, respectively). Negative sputum cultures after 2 and 3 months of therapy were 100% predictive of cure. Positive sputum cultures after 2 and 3 months were 52.3% and 84.6% predictive of failure, respectively. One patient (2.1%) relapsed after apparent cure. Twenty-five patients experienced adverse drug reactions, but only 12 of them needed drug modifications.

Conclusion:Most MDR-TB patients can be treated effectively with ofloxacin/levofloxacin-containing regimens. Presence of cavitation, resistance to ofloxacin in vitro, and poor adherence to therapy portend treatment failure. Monitoring monthly sputum culture for AFB in the initial months of chemotherapy helps predict clinical outcomes.

Key Words: multidrug resistance • ofloxacin/levofloxacin • tuberculosis

This article has been cited by other articles:

				C-Y. Chiang, D. A. Enarson, M-C. Yu, K-J. Bai, R-M. Huang, C-J. Hsu, J. Suo, and T-P. Lin Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study Eur. Respir. J., November 1, 2006; 28(5): 980 - 985. [Abstract] [Full Text] [PDF]

				H. J. Kim, C. H. Kang, Y. T. Kim, S-W. Sung, J. H. Kim, S. M. Lee, C-G. Yoo, C-T. Lee, Y. W. Kim, S. K. Han, et al. Prognostic factors for surgical resection in patients with multidrug-resistant tuberculosis Eur. Respir. J., September 1, 2006; 28(3): 576 - 580. [Abstract] [Full Text] [PDF]

				W. J. Burman, S. Goldberg, J. L. Johnson, G. Muzanye, M. Engle, A. W. Mosher, S. Choudhri, C. L. Daley, S. S. Munsiff, Z. Zhao, et al. Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis Am. J. Respir. Crit. Care Med., August 1, 2006; 174(3): 331 - 338. [Abstract] [Full Text] [PDF]

				P. C. Drobac, J. S. Mukherjee, J. K. Joseph, C. Mitnick, J. J. Furin, H. del Castillo, S. S. Shin, and M. C. Becerra Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics, June 1, 2006; 117(6): 2022 - 2029. [Abstract] [Full Text] [PDF]

				H. F. Chambers, J. Turner, G. F. Schecter, M. Kawamura, and P. C. Hopewell Imipenem for Treatment of Tuberculosis in Mice and Humans Antimicrob. Agents Chemother., July 1, 2005; 49(7): 2816 - 2821. [Abstract] [Full Text] [PDF]

				J. A. Caminero Management of multidrug-resistant tuberculosis and patients in retreatment Eur. Respir. J., May 1, 2005; 25(5): 928 - 936. [Abstract] [Full Text] [PDF]

				E. D. Chan, V. Laurel, M. J. Strand, J. F. Chan, M.-L. N. Huynh, M. Goble, and M. D. Iseman Treatment and Outcome Analysis of 205 Patients with Multidrug-resistant Tuberculosis Am. J. Respir. Crit. Care Med., May 15, 2004; 169(10): 1103 - 1109. [Abstract] [Full Text] [PDF]

				A. F. B. Cheng, W. W. Yew, E. W. C. Chan, M. L. Chin, M. M. M. Hui, and R. C. Y. Chan Multiplex PCR Amplimer Conformation Analysis for Rapid Detection of gyrA Mutations in Fluoroquinolone-Resistant Mycobacterium tuberculosis Clinical Isolates Antimicrob. Agents Chemother., February 1, 2004; 48(2): 596 - 601. [Abstract] [Full Text] [PDF]

				W. W. Yew, C. K. Chan, C. C. Leung, C. H. Chau, C. M. Tam, P. C. Wong, and J. Lee Comparative Roles of Levofloxacin and Ofloxacin in the Treatment of Multidrug-Resistant Tuberculosis: Preliminary Results of a Retrospective Study From Hong Kong Chest, October 1, 2003; 124(4): 1476 - 1481. [Abstract] [Full Text] [PDF]

				C. Mitnick, J. Bayona, E. Palacios, S. Shin, J. Furin, F. Alcantara, E. Sanchez, M. Sarria, M. Becerra, M. C. S. Fawzi, et al. Community-Based Therapy for Multidrug-Resistant Tuberculosis in Lima, Peru N. Engl. J. Med., January 9, 2003; 348(2): 119 - 128. [Abstract] [Full Text] [PDF]

				M.D. Iseman Tuberculosis therapy: past, present and future Eur. Respir. J., July 1, 2002; 20(36_suppl): 87S - 94s. [Abstract] [Full Text] [PDF]

				C.-Y. Chan, C. Au-Yeang, W.-W. Yew, M. Hui, and A. F. B. Cheng Postantibiotic Effects of Antituberculosis Agents Alone and in Combination Antimicrob. Agents Chemother., December 1, 2001; 45(12): 3631 - 3634. [Abstract] [Full Text] [PDF]

eLetters: